Andrew Brenner
Medical Oncology · Austin, TXNPI 1700909744
Payments from drug & device makers
Across 185 payments — averaging $5225.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$548K
- Seagen Inc.$245K
- Pfizer$47K
- BD$45K
- Jazz Pharmaceuticals Inc.$33K
- Novocure GmbH$32K
- plus $16K from 12 others
What the payments were for
- Consulting fees$5,0604%
- Speaking & faculty fees$103,31183%
- Travel & lodging$14,38412%
- Food & beverage$1,7451%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 6 | $548,434 |
| Seagen Inc. | 87 | $244,983 |
| Pfizer | 24 | $47,191 |
| BD | 4 | $44,793 |
| Jazz Pharmaceuticals Inc. | 17 | $33,443 |
| Novocure GmbH | 24 | $31,692 |
| Novocure Inc. | 5 | $9,875 |
| Bayer | 7 | $3,188 |
| Davol Inc. | 1 | $2,500 |
| Brainlab, Inc. | 1 | $206 |
| Johnson & Johnson | 1 | $136 |
| Telix Pharmaceuticals | 1 | $119 |
| AstraZeneca | 2 | $69 |
| E.r. Squibb & Sons, L.L.C. | 1 | $38 |
| Merck | 1 | $28 |
| GSK | 1 | $22 |
| Lilly USA, LLC | 1 | $18 |
| Incyte Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$966,748 in reported general payments places this provider in the 70th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 64 | $1,513 |
| Exemestane | 11 | $1,377 |
| Ondansetron Hcl | 39 | $1,333 |
| Levetiracetam | 35 | $1,246 |
| Prochlorperazine Maleate | 15 | $1,101 |
| Tamoxifen Citrate | 20 | $653 |
| Anastrozole | 24 | $562 |
| Dexamethasone | 23 | $494 |
| Levetiracetam ErLevetiracetam | 12 | $435 |
| Buspirone Hcl | 11 | $296 |
| Divalproex Sodium ErDivalproex Sodium | 19 | $285 |
| Gabapentin | 17 | $251 |
| Esomeprazole Magnesium | 13 | $197 |
| Divalproex Sodium | 13 | $153 |
| Sertraline Hcl | 11 | $135 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Austin
- Jason MelearAustin$14.1M
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Sawsan RashdanDallas$29.9M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.